| AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. | |
| | |
MedLine Citation:
|
PMID: 2159707 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The dideoxynucleosides 3'-azido-3'-deoxythymidine (zidovudine, AZT) and 2',3'-dideoxycytidine (ddC) are potent inhibitors of human immunodeficiency virus (HIV) in vitro and improve surrogate measures of HIV infection in vivo. Long-term administration of AZT has been associated with significant hematologic toxicity and has resulted in virus with reduced in vitro susceptibility. Although ddC does not have significant hematologic toxicity and has not shown cross-resistance with AZT in vitro, ddC has been associated with a severe dose-related peripheral neuropathy. Given the independent activity of each agent, their non-overlapping toxicity profiles, and the absence of cross-resistance, it was hypothesized that concurrent administration of AZT and ddC in low doses might be at least as active as either drug given individually at higher doses in the treatment of HIV infection. It was further hypothesized that combined low doses of both drugs would reduce the incidence of serious side effects and the development of resistance. A phase I/II dose-finding trial of six different regimens of combination AZT and ddC in persons with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex was initiated to test these hypotheses. |
| | |
Authors:
|
T C Meng; M A Fischl; D D Richman |
Related Documents
:
|
20207537 - Novel n-substituted benzimidazole cxcr4 antagonists as potential anti-hiv agents. 21994547 - Hcv animal models: a journey of more than 30 years. 17627557 - An update in the development of hiv entry inhibitors. 21713737 - Hepatitis-c and hepatitis-b co-infections in patients with human immunodeficiency virus... 8061797 - Development of transient thyroid disease and reaction during treatment of chronic hepat... 16607677 - Molecular biology of squamous cell carcinoma of the anus. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of medicine Volume: 88 ISSN: 0002-9343 ISO Abbreviation: Am. J. Med. Publication Date: 1990 May |
Date Detail:
|
Created Date: 1990-06-14 Completed Date: 1990-06-14 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 27S-30S Citation Subset: AIM; IM; X |
Affiliation:
|
University of California San Diego Treatment Center 92103. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
AIDS-Related Complex
/
drug therapy* Acquired Immunodeficiency Syndrome / drug therapy* Clinical Protocols Drug Evaluation Drug Therapy, Combination Humans Zalcitabine / administration & dosage, pharmacokinetics, therapeutic use* Zidovudine / administration & dosage, pharmacokinetics, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
30516-87-1/Zidovudine; 7481-89-2/Zalcitabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent re...
Next Document: Dideoxycytidine: current clinical experience and future prospects. A summary.